Colorectal - Metastatic - Chemotherapy
Published: Fri Oct 7, 2011 Updated:Sat Oct 15, 2011
-
Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial
SR Alberts et al; April 4, 2012; 307(13):1383-93.
-
Validation Study of a Quantitative Multigene Reverse Transcriptase–Polymerase Chain Reaction Assay for Assessment of Recurrence Risk in Patients With Stage II Colon Cancer
RG Gray et al;November 7, 2011; JCO.2010.32.8732
-
Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment
L Bennett et al; October 11, 2011, doi:10.1038/bjc.2011.409
-
Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000–05): an open-label, randomised, phase 3 trial
M Ducreux et al, The Lancet Oncology, Early Online Publication, 7 September 2011
-
Intermittent versus continuous oxaliplatin and fl uoropyrimidine combination chemotherapy for fi rst-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
RA Adams et al, June 4, 2011; doi:10.1016/S1470-2045(11)70102-4
-
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial
MT Seymour et al, May 12, 2011; doi:10.1016/S0140-6736(11)60399-1
-
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial
Seymour MT et al; July 14th, 2007;370(9582):143-52
